[1] Khoo T,Lilleker JB,Thong BY-H,Leclair V,Lamb JA,Chinoy H .2023 .Epidemiology of the idiopathic inflammatory myopathies. Nature Rev Rheumatol, 19 : 695-712.
[2] Yang Z,Lin F,Qin B,Liang Y,Zhong R. Polymyositis Y .2015 ./ dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol, 42 : 282-91.
[3] Albayda J,Demonceau G,Carlier PG .2022 .Muscle imaging in myositis: MRI, US, and PET. Best Pract Res Clin Rheumatol, 36 : 101765.
[4] Treglia G. .2019 .Diagnostic Performance of 18F-FDG PET/CT in Infectious and Inflammatory Diseases according to Published Meta-Analyses. Contrast Media Mol Imaging, : 3018349.
[5] Metser U,Tau N. Benign,Cutaneous N. Benign .2017 .Subcutaneous Lesions on FDG-PET/CT. Nucl Med, 47 : 352-61.
[6] Arai-Okuda H,Norikane T,Yamamoto Y,Mitamura K,Fujimoto K,Takami Y .2020 .18F-FDG PET/CT in patients with polymyositis/dermatomyositis: correlation with serum muscle enzymes. Eur J Hybrid Imaging, 4 : 14-7.
[7] Bektaş M,Işık EG,Oğuz E,Kemik F,Abbasgholizadeh A,İnce B .2024 .Utility of positron emission tomography as a new tool for muscle involvement in patients with idiopathic inflammatory myositis: a controlled study. Clin Exp Rheumatol, 42 : 358-66.
[8] Tanaka S,Ikeda K,Uchiyama K,Iwamoto T,Sanayama Y,Okubo A,F A .2013 .FDG uptake in proximal muscles assessed by PET/CT reflects both global and local muscular inflammation and provides useful information in the management of patients with polymyositis/ dermatomyositis. Rheumatology, 52 : 1271-8.
[9] Yildiz H,D'Abadie P,Gheysens O. .2022 .The Role of Quantitative and Semi-quantitative [18F]FDG-PET/CT Indices for Evaluating Disease Activity and Management of Patients With Dermatomyositis and Polymyositis. Front Med, 9 : 883727.
[10] Xu Y,Wang B,Zhang F,Wu M,Wang D,Shao X .2023 .18F-FDG PET-CT for the prediction of mortality in patients with dermatomyositis and without malignant tumors: a pilot study. Quant Imaging Med Surg, 13 : 3522-35.